Shopping Cart

Your shopping cart is currently empty

HAMI 3379

Name: HAMI 3379
Brand: TargetMol
SKU: T64205
Price: 149 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T64205Cas No. 1245653-57-9

Alias HAMI3379

HAMI 3379 (HAMI3379) is a selective cysteinyl leukotriene receptor 2 (CysLT2) antagonist that dose- and time-dependently attenuates brain damage and inhibits microglial cell inflammation following focal cerebral ischemia in rats and attenuates ischemia-like neuronal damage by inhibiting microglial activation.

HAMI 3379

Copy Product Info

😃Good

Purity: 99.75%

Catalog No. T64205Alias HAMI3379Cas No. 1245653-57-9

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$149	-	In Stock
2 mg	$249	6-8 weeks	6-8 weeks
5 mg	$499	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.75%

Appearance:Solid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	HAMI 3379 (HAMI3379) is a selective cysteinyl leukotriene receptor 2 (CysLT2) antagonist that dose- and time-dependently attenuates brain damage and inhibits microglial cell inflammation following focal cerebral ischemia in rats and attenuates ischemia-like neuronal damage by inhibiting microglial activation.
Targets&IC50	LTD4:3.8 nM, LTC4:4.4 nM
In vitro	HAMI 3379 effectively antagonizes LTD4- and LTC4-induced intracellular calcium mobilization in a CysLT2 receptor reporter cell line, with IC50 values of 3.8 nM and 4.4 nM, respectively. In contrast, HAMI 3379 shows minimal potency (IC50 > 10000 nM) in a recombinant CysLT1 receptor cell line and displays no agonistic activity in either CysLT receptor cell line.[1]
In vivo	0.025-0.4 mg/kg HAMI 3379, intraperitoneally, was able to significantly reduce infarct volume and decrease the percent increase in the ischemic hemisphere to contralateral hemisphere ratio over the dose range of 0.1-0.4 mg/kg. Administration of 0.1 mg/kg HAMI 3379, intraperitoneal, at 0 and 1 hour after reperfusion was effective in reducing infarct volume, alleviating cerebral edema, decreasing neurologic function scores, and enhancing grip angle. [2]
Synonyms	HAMI3379

Chemical Properties

Molecular Weight	595.72
Formula	C₃₄H₄₅NO₈
Cas No.	1245653-57-9
Smiles	C(N[C@@H]1C[C@@H](C(O)=O)CCC1)(=O)C2=C(OCCCC3=CC=C(OCCCCOC4CCCCC4)C=C3)C=CC(C(O)=O)=C2

Storage & Solubility Information

Storage

store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (134.29 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.6786 mL	8.3932 mL	16.7864 mL	83.9320 mL
5 mM	0.3357 mL	1.6786 mL	3.3573 mL	16.7864 mL
10 mM	0.1679 mL	0.8393 mL	1.6786 mL	8.3932 mL
20 mM	0.0839 mL	0.4197 mL	0.8393 mL	4.1966 mL
50 mM	0.0336 mL	0.1679 mL	0.3357 mL	1.6786 mL
100 mM	0.0168 mL	0.0839 mL	0.1679 mL	0.8393 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc